These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 19673651

  • 1. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
    Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A.
    J Infect Dis; 2009 Sep 15; 200(6):841-8. PubMed ID: 19673651
    [Abstract] [Full Text] [Related]

  • 2. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
    Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ.
    J Infect Dis; 2009 Sep 15; 200(6):849-57. PubMed ID: 19673652
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.
    Pediatr Infect Dis J; 2012 May 15; 31(5):494-500. PubMed ID: 22301476
    [Abstract] [Full Text] [Related]

  • 4. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial.
    Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A.
    Vaccine; 2009 Jan 29; 27(5):786-91. PubMed ID: 19027046
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schödel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K.
    J Am Geriatr Soc; 2007 Oct 29; 55(10):1499-507. PubMed ID: 17908055
    [Abstract] [Full Text] [Related]

  • 6. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia.
    Souza AR, Braga JA, de Paiva TM, Loggetto SR, Azevedo RS, Weckx LY.
    Vaccine; 2010 Jan 22; 28(4):1117-20. PubMed ID: 20116631
    [Abstract] [Full Text] [Related]

  • 8. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 22; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 9. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.
    J Infect Dis; 2011 Jun 15; 203(12):1719-28. PubMed ID: 21606530
    [Abstract] [Full Text] [Related]

  • 10. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D, La Fauci V, Squeri R, Cannavò G, Bacilieri S, Panatto D, Gasparini R, Amicizia D.
    J Prev Med Hyg; 2009 Jun 15; 50(2):121-6. PubMed ID: 20099444
    [Abstract] [Full Text] [Related]

  • 11. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.
    Vaccine; 2010 Jan 08; 28(3):840-8. PubMed ID: 19835829
    [Abstract] [Full Text] [Related]

  • 12. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul 08; 24(7):570-3. PubMed ID: 12975010
    [Abstract] [Full Text] [Related]

  • 13. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.
    Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M.
    Vaccine; 2009 Oct 09; 27(43):6022-9. PubMed ID: 19666152
    [Abstract] [Full Text] [Related]

  • 14. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R, Family Medicine Group of Pianiga.
    Vaccine; 2007 May 16; 25(20):3955-61. PubMed ID: 17383057
    [Abstract] [Full Text] [Related]

  • 15. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
    Zuccotti G, Amendola A, Viganò A, Pariani E, Zappa A, Pogliani L, Giacomet V, Savarino A, Podestà A, Rottoli A, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2007 Sep 17; 25(37-38):6692-8. PubMed ID: 17697730
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y.
    Vaccine; 2009 Jan 14; 27(3):454-9. PubMed ID: 19022318
    [Abstract] [Full Text] [Related]

  • 17. [Safety and immunogenicity on three lots of influenza split vaccines among adults].
    Zhang ZL, Wang X, Zhu XJ, Zhang Y, Liu Y, Gao ZG, Liang M, Li L, Li JM, Liu RK, Dong XJ, Song GX, Zhang DC, Wang WQ, Han YG, Chen JT.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun 14; 30(6):583-7. PubMed ID: 19957624
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
    Loebermann M, Anders G, Brestrich G, Fritzsche C, Klammt S, Boršo D, Frimmel S, Riebold D, Reisinger EC.
    Vaccine; 2011 Feb 01; 29(6):1228-34. PubMed ID: 21167116
    [Abstract] [Full Text] [Related]

  • 19. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR, Colberg K, Frick M, Preusche A.
    Infection; 2004 Aug 01; 32(4):191-8. PubMed ID: 15293073
    [Abstract] [Full Text] [Related]

  • 20. Response to a monovalent 2009 influenza A (H1N1) vaccine.
    Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL.
    N Engl J Med; 2009 Dec 17; 361(25):2405-13. PubMed ID: 19745216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.